# Effectiveness of Biosimilar Ranibizumab in the Management of Diabetic Macular Edema

> **NCT07663370** · — · COMPLETED · sponsor: **Benha University** · enrollment: 60 (actual)

## Conditions studied

- Anti-VEGF Treatment
- Ranibizumab
- Biosimilar

## Interventions

- **DRUG:** Ranibizumab biosimilar

## Key facts

- **NCT ID:** NCT07663370
- **Lead sponsor:** Benha University
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2022-01-01
- **Primary completion:** 2026-04-01
- **Final completion:** 2026-04-15
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2026-06-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07663370

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07663370, "Effectiveness of Biosimilar Ranibizumab in the Management of Diabetic Macular Edema". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07663370. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*